How Oxymetholone (Anadrol) Affects HDL Cholesterol

Oxymetholone suppresses HDL via a combination of mechanisms that make it among the most lipid-toxic oral steroids:

1. Potent HTGL upregulation via first-pass hepatic metabolism: As a 17-alpha-alkylated oral, oxymetholone delivers a heavily concentrated androgenic signal to hepatocytes on first pass. Oxymetholone's high anabolic-to-androgenic ratio in muscle does not protect the liver from its androgen-receptor-mediated HTGL stimulation.
2. ApoA-I suppression: Like other 17-AA orals, oxymetholone reduces ApoA-I synthesis, impairing de novo HDL particle formation.
3. No estrogenic buffer despite structural similarity to estrogens: Although oxymetholone has a structural resemblance to estrogen-derived compounds, it does not aromatise to oestradiol in the conventional pathway. Instead, it undergoes some conversion to a methylestrogen via an alternative metabolic route, but this provides minimal to no clinically meaningful estrogenic protection for lipids. The net estrogenic contribution to HDL protection is negligible, unlike Dianabol.
4. Concurrent hepatotoxicity amplification: Oxymetholone is one of the most hepatotoxic AAS, producing ALT and AST elevations that reflect widespread hepatocellular damage. Hepatocytes that are simultaneously damaged by direct toxicity are less capable of normal lipid metabolism, compounding the HTGL-mediated HDL catabolism.

The combination of potent HTGL upregulation, ApoA-I suppression, absent estrogenic protection, and hepatotoxic impairment of hepatocellular lipid metabolism places oxymetholone at the highest end of the oral steroid lipid-toxicity spectrum.

At 50 mg/day (lower bodybuilding dose):

• Severe HDL suppression: 40-60%+ from baseline
• Case reports document HDL below 20 mg/dL (Achar 2010)
• LDL elevation often accompanies the HDL suppression, compounding the atherogenic ratio

At 100 mg/day (common bodybuilding dose):

• Expect HDL below 20 mg/dL in the majority of users
• The total cholesterol/HDL ratio may exceed 10:1, representing extreme atherogenic risk
• Triglycerides often rise simultaneously, reflecting broad hepatic lipid metabolism impairment

Timing: Effects are rapid. First-pass mechanism means measurable HTGL changes occur within days. Significant HDL falls are documented within the first 2-4 weeks.

Concurrent liver marker worsening: ALT and AST often deteriorate in parallel with the lipid changes, reflecting the same underlying hepatocellular stress driving both outcomes.

Baseline lipid panel and liver markers (ALT, AST, GGT) are both mandatory before starting:

• Do not start oxymetholone with pre-existing dyslipidemia or elevated liver enzymes

On cycle:

• Check lipids AND liver markers at week 3-4; both deteriorate rapidly and in parallel
• If HDL has fallen below 20 mg/dL or ALT exceeds 3x the upper limit of normal, discontinuation is strongly recommended

Cycle length:

• Do not use oxymetholone beyond 4-6 weeks without re-evaluating lipid and liver status. The combination of hepatotoxicity and lipid damage that accumulates after this point significantly increases cardiovascular and hepatic risk.

During cycle (harm reduction):

• Limit cycles to 4 weeks if possible. Six weeks should be the maximum.
• Never stack with other hepatotoxic orals (stanozolol, Dianabol, superdrol). The combined hepatotoxicity and lipid effects are additive and potentially dangerous.
• Aggressive cardiovascular exercise protocol: 30-45 minutes, 4-5 times per week of moderate-intensity cardio
• Omega-3 fatty acids: 3-4 g EPA/DHA daily
• Monitor liver markers (ALT/AST/GGT) concurrently; lipid and liver damage tend to progress together, and either can be a trigger to stop early
• TUDCA (tauroursodeoxycholic acid) 500-1000 mg/day is often used for hepatoprotection during oxymetholone cycles, though evidence for this specific indication is indirect

Post-cycle:

• Allow full lipid and liver recovery before starting any subsequent cycle; this may take 8-16 weeks
• Both HDL and liver enzymes should return to near-baseline before resuming any hepatotoxic compound